$DD

DD Downgraded by JP Morgan -- Price Target Lowered to $145

JP Morgan downgraded DuPont de Nemours (DD) to Neutral, lowering its price target from $172 to $145. GuruFocus estimates DD is 83.5% overvalued, with a GF Value of $70.97 vs. current price of $130.24. DD's P/E (TTM) is 309.35x, far above its 5-year median of 7.91x. Analysts cite concerns about growth and profitability.

Original reporting
Published Oct 9, 2026, 7:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$DD
Bearish
medium confidence
Mentioned
$DD
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$DDBearishMed
01

Why it matters

The downgrade could trigger short‑term selling pressure, but the long‑term impact depends on execution of growth initiatives.

02

Market read

Analyst downgrade with a lower price target may prompt traders to reassess DD positions.

03

What to watch

Potential upside from upcoming product launches or cost‑cutting initiatives not reflected in the downgrade.

Relevance 7/10Novelty 6/10Timing: immediate post‑release

Background

DuPont de Nemours is a diversified specialty chemicals company with a market cap of ~$17.6 B. The article recaps a JP Morgan analyst rating change.

Company-level read

Ticker impact

$DDBearishMedium confidence
Context

JP Morgan downgraded DuPont de Nemours (DD) to Neutral and cut the price target to $145.

Expected impact

likely pressure as investors price in the reduced target

Evidence & confidence

Analyst downgrade with a 15.7% target reduction signals weaker outlook, prompting sell interest.

Market effects

May weigh on the basic materials/chemicals sector as peers could face similar scrutiny.

Limited to US markets where DD trades; broader market impact minimal.

Low, as DuPont is a mid‑cap specialty chemicals firm.

Counterpoint

Some investors may view the downgrade as overdone given DD's cash flow and market position.

Key entities

  • DuPont de Nemours

    Specialty chemicals and materials producer.

  • JP Morgan

    Financial institution providing the downgrade.

Related articles

$DDHigh

JPMorgan downgrades DuPont stock rating on recovery outlook

JPMorgan downgraded DuPont (NYSE:DD) to Neutral from Overweight, lowering its price target to $145 from $172. The stock trades at $132.48, considered undervalued. DuPont reported Q2 2026 earnings, beating estimates with $1.88 EPS and $1.82B revenue. BMO Capital reiterated its Outperform rating, maintaining a $186 price target.

$DDMed

Attorney General Todd Rokita leads multistate coalition to stop DuPont shell game, hold companies accountable for PFAS contamination

Attorney General Todd Rokita led a 16-state lawsuit against DuPont (EIDP), Corteva, and Vylor, alleging a transfer of assets to avoid PFAS contamination liabilities. The suit seeks to freeze assets and block dividends or buybacks. Rokita claims the companies moved valuable assets to Vylor, leaving liabilities with DuPont. The hearing is set for October 2, 2026.

$DDLow

Judge says 3M, DuPont, and Honeywell must face Connecticut firefighters' PFAS claims

A U.S. judge ruled that 3M, DuPont, Honeywell, and others must face claims from Connecticut firefighters over PFAS exposure in protective gear. The lawsuit alleges the gear, containing 3M's Scotchlite and DuPont's Kevlar, increased cancer risks. The judge allowed the case to proceed, permitting damages and medical monitoring claims. The companies argue the gear served its protective function. PFAS makers face broader scrutiny, with prior settlements totaling over $11 billion.

$CCMedAI 8/10

North Carolina, Chemical Companies Reach $455M PFAS Contamination Settlement

Chemours, DuPont, and Corteva agreed to pay $455M over 15 years to settle PFAS contamination claims in North Carolina. Chemours will cover half, with the rest split between DuPont and Corteva. The funds will support state and local remediation efforts. The companies have already spent or committed significant sums for cleanup and penalties.